Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Neuromuscular Disorders Market Growth Analysis: How Will Revenue Expand During The Forecast Period?
The market for neuromuscular disorders has experienced significant growth in recent years. It is projected to expand from $8.31 billion in 2025 to $8.98 billion in 2026, achieving a compound annual growth rate (CAGR) of 8.0%. This historical expansion can be attributed to the rising occurrence of genetic neuromuscular conditions, enhanced awareness leading to prompt diagnosis and treatment options, a surging demand for effective therapies for rare disorders, increased research efforts in muscular dystrophy and ALS, and the growing adoption of advanced diagnostic technologies.
The neuromuscular disorders market is poised for substantial growth over the next few years, with projections indicating it will expand to $12.07 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 7.7%. This forecasted expansion is driven by several factors, including increasing patient advocacy and support group involvement, a rising demand for biologics and gene therapies, greater recognition of neuromuscular disorders in pediatric settings, escalating government initiatives for rare disease management, and an enhanced focus on home-based care and rehabilitation services. Significant trends anticipated during this period involve progress in gene-editing technologies for targeted therapies, innovation within RNA-based treatment platforms, the integration of AI for more rapid neuromuscular diagnosis, advancements in stem-cell-based regenerative treatments, and novel developments in wearable devices for continuous patient monitoring.
Download A Free Sample Report For Comprehensive Market Insights:
Neuromuscular Disorders Market Expansion Supported By Key Demand Factors
The increasing requirement for tailored medical interventions is anticipated to fuel the expansion of the neuromuscular disorders market in the future. Personalized medicine represents a healthcare approach focused on customizing treatments for individual patients, considering their genetic makeup, environmental influences, and lifestyle choices to optimize therapeutic outcomes and enhance care quality. The heightened need for personalized medicine stems from breakthroughs in genomic technologies, which facilitate the accurate identification of genetic variations, thereby enabling individualized treatment plans. This approach significantly improves the management of neuromuscular disorders by allowing treatments to be specifically adapted to each patient’s genetic, molecular, and physiological characteristics. It leads to better patient results by providing targeted therapies, maximizing effectiveness, and reducing unwanted side effects. For instance, in February 2024, data from the Personalized Medicine Coalition (PMC), a US-based nonprofit organization, indicated that the U.S. Food and Drug Administration (FDA) sanctioned 26 novel personalized medicines in 2023, marking a considerable increase from the 12 approved in 2022. Consequently, the growing demand for personalized medicine is propelling the development of the neuromuscular disorders market.
Neuromuscular Disorders Market Segment Analysis And Revenue Opportunities
The neuromuscular disorders market covered in this report is segmented –
1) By Disease Type: Spinal Muscular Atrophy (SMA), Amyotrophic Lateral Sclerosis (ALS), Duchenne Muscular Dystrophy (DMD), Myasthenia Gravis, Other Muscular Dystrophies
2) By Product Type: Pharmaceuticals, Biologics, Diagnostic Tools, Assistive Devices
3) By Route of Administration: Oral, Injectable, Other Route of Administrations
4) By Treatment: Gene Therapy, Drug Therapy, RNA-Based Therapy, Enzyme Replacement Therapy, Physical Therapy And Rehabilitation, Respiratory Care
Subsegments:
1) By Spinal Muscular Atrophy: SMA Type 1, SMA Type 2, SMA Type 3, SMA Type 4, SMA with Respiratory Distress (SMARD)
2) By Amyotrophic Lateral Sclerosis: Sporadic ALS, Familial ALS, Limb-Onset ALS, Bulbar-Onset ALS, Respiratory-Onset ALS
3) By Duchenne Muscular Dystrophy: Early-Onset DMD, Late-Onset DMD, Exon Deletion Mutations, Exon Duplication Mutations, Point Mutations
4) By Myasthenia Gravis: Generalized Myasthenia Gravis, Ocular Myasthenia Gravis, Seropositive MG, MuSK-Positive MG, Seronegative MG
5) By Other Muscular Dystrophies: Becker Muscular Dystrophy (BMD), Limb-Girdle Muscular Dystrophy (LGMD), Facioscapulohumeral Muscular Dystrophy (FSHD), Congenital Muscular Dystrophies, Myotonic Dystrophy
Neuromuscular Disorders Market Growth Trends Influencing Competitive Dynamics
Leading companies active in the neuromuscular disorders market are concentrating on developing advanced treatments, such as gene replacement therapies, to address the fundamental genetic origins of conditions like Duchenne muscular dystrophy and spinal muscular atrophy. Gene replacement therapy involves engineered biological products that deliver functional copies of defective genes to restore or improve muscle function in patients with inherited neuromuscular conditions, providing a potential one-time treatment that reduces the need for long-term chronic therapy. For instance, in November 2025, Novartis, a Switzerland-based pharmaceuticals company, obtained US Food and Drug Administration (FDA) approval for Itvisma (onasemnogeneabeparvovec-brve), representing the first and only gene replacement therapy available for treating children two years of age and older, teens, and adults with spinal muscular atrophy (SMA) who have a confirmed mutation in the survival motor neurone 1 (SMN1) gene. This therapy is specifically designed to address the underlying genetic cause of SMA with a single, fixed dosage that does not require adjustments based on body weight or age. Itvisma can enhance motor function by substituting the SMN1 gene, which may diminish the necessity for long-term medication used in conjunction with other current treatments for this population.
Neuromuscular Disorders Market Leading Players Shaping Industry Direction
Major companies operating in the neuromuscular disorders market are AbbVie Inc., Novartis AG, Takeda Pharmaceutical Company Limited, The Trustees of the University of Pennsylvania, Biogen Inc., Sarepta Therapeutics Inc., argenx SE, PTC Therapeutics Inc., Catalyst Pharmaceuticals Inc., Mayo Clinic Laboratories, Fulgent Genetics Inc., Dyne Therapeutics Inc., The Regents of the University of California, GeneDx LLC, PepGen Inc., Centogene N.V., Scholar Rock Holding Corporation, Solid Biosciences Inc., Vita Therapeutics Inc., NMD Pharma A/S, Cytokinetics Incorporated, Sudo Biosciences Inc.
Access The Complete Neuromuscular Disorders Market Report:
Neuromuscular Disorders Market Geographic Landscape: Which Region Dominates Industry Growth?
North America was the largest region in the neuromuscular disorders market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neuromuscular disorders market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model